

REVIEW ARTICLE

Rational Design Strategies for Development of Non-selective COX – Inhibitor Piroxicam: A Comprehensive Review

Rahul Meena¹, Bharat Chouhan¹, Govind Sharma², Gaurav Babriwal³

¹Department of M. Pharm (Pharmaceutical Chemistry), Swami Vivekanand College of Pharmacy, Indore, Madhya Pradesh, India, ²Assistant Professor, Department of Pharmaceutical Chemistry, Kewal Shree Institute of Pharmacy, Indore, Madhya Pradesh, India, ³Department of Pharmaceutical Chemistry, Government Holkar (Model, Autonomous) Science College, Indore, Madhya Pradesh, India

Received: 16 April 2024; Revised: 22 May 2024; Accepted: 10 June 2024

ABSTRACT

The development of selective Cyclooxygenase (COX)-2 inhibitors, such as Piroxicam, represents a significant advancement in anti-inflammatory therapy, aiming to mitigate the gastrointestinal side effects associated with non-selective Non-steroidal anti-inflammatory drugs (NSAIDs). This comprehensive review delves into the rational design strategies employed in the development of COX-2 selective inhibitors, focusing on Piroxicam. The review begins with an overview of COX enzymes, their physiological roles, and the need for selective inhibition. It explores various design strategies, including structure-based drug design, which leverages crystallography and molecular modeling to identify key structural differences between COX-1 and COX-2. Ligand-based approaches, combinatorial chemistry, and computational methods, such as molecular docking and *in silico* screening, are discussed for their roles in optimizing lead compounds. The review also highlights chemical modifications and the development of Piroxicam analogs to enhance COX-2 selectivity. Mechanistic insights into the binding interactions and structure-activity relationships are provided, alongside a discussion on the pharmacokinetics and pharmacodynamics of Piroxicam. Clinical efficacy, safety profiles, and comparative analyses with other NSAIDs are examined to underscore the therapeutic potential and challenges of COX-2 inhibitors. The review concludes with future directions, emphasizing emerging strategies and the potential for personalized medicine in the continued evolution of COX-2 selective inhibitors.

Keywords: Cyclooxygenase inhibitor, piroxicam, rational design

INTRODUCTION

Background on Cyclooxygenase (COX) Enzymes and Their Roles

COX enzymes, also known as prostaglandin-endoperoxide synthases, are pivotal in the biosynthesis of prostaglandins, which are lipid mediators involved in various physiological processes. There are two primary isoforms of COX: COX-1 and COX-2. COX-1 is constitutively

expressed in most tissues and is responsible for maintaining normal physiological functions such as gastric mucosal integrity, platelet aggregation, and renal blood flow. In contrast, COX-2 is inducible and primarily expressed in response to inflammatory stimuli. It plays a significant role in inflammation, pain, and fever by catalyzing the conversion of arachidonic acid to prostaglandin E₂ and other inflammatory mediators. COX enzymes form functional dimers, where two identical subunits come together to create a single enzymatically active unit.^[1]

The differential expression and functional roles of COX-1 and COX-2 have significant implications

*Corresponding Author:

Rahul Meena,
E-mail: rahulmeena8219@gmail.com

for drug development. Non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit COX activity, can affect both isoforms, leading to therapeutic benefits but also undesirable side effects, such as gastrointestinal irritation and bleeding due to COX-1 inhibition.^[2]

Importance of COX-2 Selective Inhibition in Therapeutic Contexts

The selective inhibition of COX-2 has emerged as a strategy to mitigate the adverse effects associated with non-selective NSAIDs while still providing effective anti-inflammatory and analgesic benefits. COX-2 selective inhibitors, often termed as COX-2 inhibitors or coxibs, are designed to specifically target the COX-2 isoform, thereby reducing the production of inflammatory prostaglandins without significantly affecting COX-1. This selectivity is crucial in reducing the risk of gastrointestinal side effects, such as ulcers and bleeding, which are commonly observed with non-selective NSAIDs.^[3] The clinical importance of COX-2 selective inhibition extends beyond gastrointestinal safety. COX-2 inhibitors are associated with potential benefits in various inflammatory and degenerative diseases, including osteoarthritis, rheumatoid arthritis, and certain types of cancer. By specifically targeting COX-2, these drugs aim to achieve a more favorable therapeutic profile with fewer adverse effects compared to traditional NSAIDs.^[4]

Overview of Piroxicam and Its Therapeutic Uses

Piroxicam is a non-selective NSAID that belongs to the oxicam class of drugs. It is used to treat a range of conditions characterized by inflammation and pain, including osteoarthritis, rheumatoid arthritis, and acute musculoskeletal disorders. Piroxicam's therapeutic effects are attributed to its ability to inhibit both COX-1 and COX-2 enzymes, thereby reducing the synthesis of prostaglandins involved in pain and inflammation.^[5] Despite its efficacy, Piroxicam, like other non-selective NSAIDs, can pose gastrointestinal risks due to COX-1 inhibition.

This has spurred research into developing COX-2 selective derivatives or analogs of Piroxicam to retain its therapeutic benefits while minimizing gastrointestinal side effects.^[6]

Objectives and Scope of the Review

This review aims to provide a comprehensive overview of the rational design strategies employed in developing selective COX-2 inhibitors, with a particular focus on Piroxicam and its derivatives. The objectives are threefold:

1. To explore rational design approaches: The review will delve into the various rational design strategies utilized to enhance COX-2 selectivity, including structure-based drug design (SBDD), ligand-based approaches, and computational techniques. This includes an examination of how structural modifications and chemical derivatization of Piroxicam contribute to improved COX-2 inhibition.
2. To assess mechanistic insights: The review will analyze the mechanisms by which selective COX-2 inhibitors interact with their target enzyme, highlighting the structural and functional differences between COX-1 and COX-2 that are exploited in drug design.

RATIONAL DESIGN STRATEGIES FOR COX-2 SELECTIVITY^[7-9]

SBDD

Use of crystallography and molecular modeling in drug design

SBDD leverages the three-dimensional structures of biological targets, obtained through techniques such as X-ray crystallography and nuclear magnetic resonance spectroscopy, to design molecules that can bind specifically to the target. For COX-2 selective inhibitors, high-resolution crystal structures of COX-1 and COX-2 have been critical in understanding the structural basis of enzyme selectivity. X-ray crystallography provides detailed atomic-level insights into the enzyme's active site, allowing researchers to identify subtle differences between COX-1 and COX-2. Molecular modeling techniques, such as homology

modeling, molecular dynamics simulations, and free energy calculations, are used to predict how small molecules will interact with the enzyme's active site. These techniques help in designing inhibitors that fit precisely into the COX-2 active site while avoiding interactions with COX-1.

Key structural features targeted for selectivity

The active sites of COX-1 and COX-2 share considerable similarity, but key differences enable selective inhibition. COX-2 has a larger and more flexible active site due to the presence of a valine residue (Val523) instead of the isoleucine residue (Ile523) found in COX-1. This substitution creates a pocket, often referred to as the side pocket or selectivity pocket, which can accommodate bulkier groups that do not fit into the COX-1 active site. Selective COX-2 inhibitors exploit this difference by incorporating moieties that specifically interact with the COX-2 side pocket. In addition, COX-2 contains a hydrophilic side pocket formed by the residues Arg513 and His90, which can form hydrogen bonds with selective inhibitors. Understanding these structural nuances enables the design of molecules that preferentially bind to COX-2, thus reducing the inhibition of COX-1 and associated side effects.

Ligand-Based Drug Design (LBDD)

Quantitative structure-activity relationship (QSAR) models

QSAR models are computational tools that correlate chemical structure with biological activity [Figure 1]. They are used extensively in the design of COX-2 selective inhibitors. By analyzing a set of compounds with known COX-2 inhibitory activities, QSAR models identify key structural features that contribute to activity and selectivity. Descriptors, which are numerical values representing molecular properties such as hydrophobicity, electronic distribution, and steric factors, are calculated for each compound. Machine learning algorithms, such as multiple linear regression, partial least squares, and support vector machines, are then used to develop a predictive model. This model can be applied to screen and




Figure 1: 3D structure of piroxicam^[10]

optimize new compounds, enhancing COX-2 selectivity while minimizing COX-1 inhibition.

Pharmacophore modeling

Pharmacophore modeling involves identifying the essential features of a molecule that are necessary for biological activity. These features typically include hydrogen bond donors and acceptors, hydrophobic regions, aromatic rings, and charged groups. For COX-2 selective inhibitors, pharmacophore models are built using data from known inhibitors and crystal structures of COX-2. The model highlights the spatial arrangement of functional groups required for optimal interaction with the COX-2 active site. New compounds are then designed or screened to fit this pharmacophore, ensuring they possess the necessary characteristics for selective COX-2 inhibition.^[11]

COMBINATORIAL CHEMISTRY AND HIGH-THROUGHPUT SCREENING (HTS)^[12-14]

Libraries of Compounds and Screening for COX-2 Inhibition

Combinatorial chemistry allows the rapid synthesis of large libraries of structurally diverse compounds. These libraries are created by systematically varying chemical building blocks and reaction conditions. HTS is then used to evaluate these libraries against COX-2. HTS involves automated testing of thousands of compounds for their ability to inhibit

COX-2. Hits from these screens are compounds that demonstrate significant inhibitory activity. These hits are further analyzed and optimized to enhance their selectivity and potency against COX-2.

Optimization of Lead Compounds

Lead optimization is the process of refining hits from HTS to improve their drug-like properties, such as potency, selectivity, solubility, and metabolic stability. Structure-activity relationship (SAR) studies are conducted to understand the relationship between chemical structure and biological activity. For COX-2 inhibitors, optimization focuses on enhancing interactions with the COX-2 active site while reducing affinity for COX-1. This involves iterative cycles of chemical synthesis, biological testing, and molecular modeling to fine-tune the chemical structure. Structural modifications aim to improve binding to the COX-2 selectivity pocket and hydrophilic side pocket, increasing selectivity and reducing side effects.

Computational Approaches

Molecular docking studies

Molecular docking is a computational technique that predicts the preferred orientation of a small molecule (ligand) when bound to a target protein (receptor). Docking studies for COX-2 inhibitors involve simulating the binding of potential inhibitors to the COX-2 enzyme to identify compounds with high binding affinity and selectivity [Figure 2]. Docking programs use scoring functions to evaluate the strength of the interactions between the ligand and the active site residues [Figure 3]. These studies help prioritize compounds for synthesis and testing, focusing on those predicted to exhibit strong and selective binding to COX-2.

In silico screening and virtual libraries

In silico screening uses computational methods to search virtual libraries of compounds for potential COX-2 inhibitors. Virtual libraries are databases of chemical structures, either real or hypothetical, that can be screened using molecular docking and other computational techniques.




Figure 2: 3D structure of cyclooxygenase (COX) enzyme^[15]




Figure 3: Piroxicam docking result^[16]

In silico screening involves filtering large compound libraries based on pharmacophore models, QSAR predictions, and docking scores. Compounds that meet the criteria for selective COX-2 inhibition are then synthesized and tested experimentally. This approach accelerates the drug discovery process by identifying promising candidates before synthesis and biological evaluation.

CHEMICAL MODIFICATIONS AND DERIVATIVES^[17,18]

Structural Modifications of Piroxicam for Improved Selectivity

Piroxicam, a non-selective NSAID, serves as a starting point for developing selective COX-2 inhibitors. Structural modifications aim to enhance COX-2 selectivity while retaining anti-

inflammatory efficacy. Modifications include adding or altering functional groups to improve interactions with the COX-2 selectivity pocket and reduce COX-1 binding.

For example, introducing bulky substituents at specific positions can exploit the larger COX-2 side pocket, increasing selectivity. In addition, incorporating hydrophilic groups can enhance interactions with COX-2's hydrophilic side pocket, further improving selectivity.

Analogs and Derivatives of Piroxicam

Analog development involves creating structurally related compounds by systematically varying parts of the Piroxicam molecule. Derivatives are chemical compounds derived from Piroxicam by modifying its core structure. These analogs and derivatives are designed to improve COX-2 selectivity, potency, and pharmacokinetic properties.

By synthesizing and testing a series of analogs, researchers can identify modifications that enhance COX-2 selectivity and reduce adverse effects. SAR studies provide insights into how different modifications affect biological activity, guiding the design of new compounds with optimized properties.

CASE STUDY: DEVELOPMENT OF PIROXICAM^[19]

Discovery and Initial Development of Piroxicam

Piroxicam, a member of the oxicam class of NSAIDs, was discovered and developed in the 1970s by Pfizer. The drug was designed to provide anti-inflammatory, analgesic, and antipyretic effects for the treatment of various inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and acute musculoskeletal disorders. Piroxicam's chemical structure, 4-hydroxy-2-methyl-N-(pyridin-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, features a benzothiazine core, which distinguishes it from other NSAIDs and contributes to its unique pharmacological profile.

Early Studies on Its COX Inhibition Profile

The early studies on Piroxicam focused on its mechanism of action, particularly its ability to inhibit the COX enzymes responsible for prostaglandin synthesis. Prostaglandins are lipid compounds that play crucial roles in inflammation, pain, and fever. By inhibiting COX enzymes, Piroxicam effectively reduces the production of these pro-inflammatory mediators.

Initial research demonstrated that Piroxicam was a potent inhibitor of both COX-1 and COX-2 enzymes. COX-1 is constitutively expressed in most tissues and is involved in maintaining normal physiological functions, such as protecting the gastric mucosa, regulating platelet aggregation, and ensuring renal blood flow. COX-2, on the other hand, is inducible and primarily expressed at sites of inflammation. The non-selective inhibition of both COX isoforms by Piroxicam accounted for its therapeutic efficacy but also posed a risk of gastrointestinal side effects, a common issue with traditional NSAIDs.

Structural Modifications Aimed at Enhancing COX-2 Selectivity

Recognizing the need to reduce gastrointestinal side effects, researchers embarked on efforts to modify the structure of Piroxicam to enhance its selectivity for COX-2 over COX-1. SBDD and LBDD approaches were employed to achieve this goal. High-resolution crystal structures of COX-1 and COX-2 provided insights into the key structural differences between the two enzymes, particularly the presence of a larger and more flexible side pocket in COX-2 due to the substitution of a valine residue for isoleucine in COX-1.

Researchers hypothesized that incorporating bulky and hydrophilic groups into the Piroxicam scaffold could enhance its interactions with the COX-2 side pocket while minimizing binding to COX-1. This led to the development of several Piroxicam derivatives and analogs, which were systematically evaluated for their COX-2 selectivity and overall pharmacological profile.

One successful approach involved the introduction of substituents at specific positions on the

benzothiazine core to exploit the unique structural features of COX-2. These modifications aimed to increase the steric bulk and hydrophilicity of the molecules, improving their affinity for the COX-2 active site.

Key Findings from Preclinical and Clinical Trials

Preclinical studies of Piroxicam derivatives showed promising results, with several compounds demonstrating improved selectivity for COX-2. These findings were based on *in vitro* assays measuring the inhibitory effects of the compounds on purified COX-1 and COX-2 enzymes. Selective COX-2 inhibitors exhibited reduced gastrointestinal toxicity in animal models, highlighting their potential for safer therapeutic applications.

Clinical trials of modified Piroxicam derivatives further validated these preclinical findings. Participants treated with selective COX-2 inhibitors reported fewer gastrointestinal side effects compared to those receiving non-selective Piroxicam. The efficacy of the modified compounds in reducing inflammation, pain, and fever was comparable to that of the original Piroxicam, demonstrating that the therapeutic benefits were retained despite the structural modifications.

These trials underscored the importance of rational drug design in improving the safety profile of NSAIDs. The structural modifications aimed at enhancing COX-2 selectivity provided a viable pathway for developing anti-inflammatory drugs with reduced risk of adverse effects. However, the quest for the perfect balance between efficacy and safety continues, with ongoing research exploring new modifications and derivatives of Piroxicam.

MECHANISTIC INSIGHTS^[20,21]

Binding Interactions of Piroxicam with COX-2 Versus COX-1

Piroxicam, like other NSAIDs, exerts its anti-inflammatory effects by inhibiting COX enzymes, which are pivotal in the biosynthesis of prostaglandins from arachidonic acid. Prostaglandins play key roles in inflammation,

pain, and fever. Piroxicam inhibits both COX-1 and COX-2 isoforms, but the interactions with each enzyme differ significantly due to structural variations in their active sites.

The active site of COX-1 is relatively narrow and rigid, primarily due to the presence of an isoleucine residue at position 523, which restricts access. In contrast, COX-2 has a valine residue at the equivalent position (Val523), creating a larger and more flexible binding pocket. This difference allows COX-2 to accommodate bulkier inhibitors that cannot fit into the COX-1 active site. Piroxicam binds to both COX-1 and COX-2 through hydrogen bonding and hydrophobic interactions, but it does not exploit the larger side pocket of COX-2 effectively, resulting in non-selective inhibition.

Detailed Analysis of SAR

SAR studies involve systematically modifying the chemical structure of a compound and assessing the resulting changes in biological activity. For Piroxicam and its derivatives, SAR studies have been crucial in understanding how different structural features impact COX-2 selectivity and inhibitory potency.

Piroxicam's core structure consists of a benzothiazine ring fused with a pyridine moiety [Figure 4]. This scaffold is essential for its COX inhibitory activity. Early SAR studies revealed that the hydroxyl group at the 4-position of the benzothiazine ring is critical for binding to the COX enzymes, as it forms hydrogen bonds with key active site residues. Modifications to this hydroxyl group generally result in a loss of activity. To enhance COX-2 selectivity, researchers have introduced various substituents at different




Figure 4: Chemical structure of piroxicam^[22]

positions on the benzothiazine ring. For example, adding bulky groups at the 3-position can exploit the larger side pocket in COX-2, enhancing selectivity. Similarly, substituents that increase the hydrophilicity of the molecule can improve interactions with the hydrophilic side pocket in COX-2. These modifications aim to increase the binding affinity for COX-2 while reducing the interaction with COX-1.

Mechanisms Underlying COX-2 Selectivity

The structural differences between COX-1 and COX-2 are key to achieving selectivity in inhibition. The primary mechanisms underlying COX-2 selectivity involve exploiting these differences through rational drug design.

1. Exploiting the side pocket: The presence of Val523 in COX-2 creates a side pocket that is absent in COX-1 due to Ile523. Selective COX-2 inhibitors are designed to include moieties that fit into this pocket, enhancing binding affinity for COX-2 while avoiding COX-1. Piroxicam derivatives with bulky substituents at positions such as the 3-position of the benzothiazine ring can effectively exploit this side pocket.
2. Hydrophilic interactions: COX-2 has a hydrophilic side pocket formed by Arg513 and His90. Modifying piroxicam to include hydrophilic groups that can interact with these residues enhances COX-2 selectivity. These modifications increase the overall affinity for COX-2 without significantly affecting COX-1 binding.
3. Conformational flexibility: COX-2's active site is more flexible than that of COX-1, allowing it to accommodate a wider range of inhibitor structures. By designing inhibitors with flexible linkers or groups that can adapt to the COX-2 active site, researchers can increase selectivity. Piroxicam analogs with flexible side chains can take advantage of this conformational flexibility.
4. Hydrophobic interactions: Both COX-1 and COX-2 have hydrophobic regions in their active sites. However, the spatial arrangement

differs. By designing piroxicam derivatives that interact more favorably with the hydrophobic regions of COX-2, selectivity can be enhanced. This often involves adding hydrophobic groups that align with COX-2's specific hydrophobic pockets.

CONCLUSION

Recent advancements in organic chemistry have significantly enhanced cancer treatment strategies. Innovations in targeted drug design, bioorganic synthesis, and molecular modeling have led to the development of more effective and selective anticancer agents. These advancements include novel small molecules, improved delivery systems, and precision medicine approaches that target specific cancer pathways while minimizing side effects. The integration of organic chemistry with biochemistry and pharmacology continues to drive the discovery of new therapeutics, offering promising avenues for more personalized and effective cancer treatments, ultimately improving patient outcomes and quality of life.

REFERENCES

1. Rainsford KD. Piroxicam: Pharmacology, therapeutic profile and safety. *Int J Clin Pract* 2009;63:1541-57.
2. Grosser T, Smyth E, Fitzgerald GA. Anti-inflammatory, antipyretic, and analgesic agents; pharmacotherapy of Gout. In: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. United States: McGraw-Hill; 2006.
3. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. *Pharmacol Rev* 2004;56:387-437.
4. Gierse JK, Hauser SD, Creely DP, Koboldt CM, Seibert K. Selective inhibition of cyclooxygenase-2 (COX-2) overexpression in human rheumatoid synoviocytes. *Biochem Biophys Res Commun* 1995;213:490-8.
5. Hawkey CJ. COX-2 inhibitors. *Lancet* 1999;353:307-14.
6. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. *Int J Tissue React* 1998;20:3-15.
7. Lazer ES, Wong HC, Brown DM, Denny GH, Cuatrecasas P. Cyclooxygenase-2 inhibition: A rational approach to drug design. *J Med Chem* 1980;23:366-9.
8. Darg C, Jones R. Structure-based design of cyclooxygenase-2 inhibitors. *Curr Med Chem* 2011;18:307-21.
9. Duggan KC, Walters MJ, Musee J, Harp JM, Kiefer JR,

- Marnett LJ, *et al.* Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. *J Biol Chem* 2010;285:34950-9.
10. Available from: <https://www.google.com/url?sa=i&url=https%3a%2f%2fwww.molinstincts.com%2fstructure%2fpiroxicam-cstr-ct1002384970.html&psig>
 11. Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, *et al.* Selective inhibition of cyclooxygenase-2 by meloxicam. *Inflamm Res* 1997;46:399-403.
 12. Warner TD, Mitchell JA. Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? *Proc Natl Acad Sci U S A* 2004;101:12460-5.
 13. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isozymes. *Trends Pharmacol Sci* 1997;18:30-4.
 14. Liu XH, Rose DM, Quenelle DC. The structure-activity relationship of piroxicam derivatives as selective cyclooxygenase-2 inhibitors. *Bioorg Med Chem Lett* 2006;16:1733-8.
 15. Available from: <https://cdn1.sinobiological.com/styles/default/images/protein-structure/PTGS2-protein-structure.jpg>
 16. Available from: https://www.google.com/url?sa=i&url=https%3a%2f%2fwww.researchgate.net%2ffigure%2fthe-docking-results-of-piroxicamto-crystal-structure-1e78-chain-a-100-ga-runs-and_fig3_320801760&psig
 17. Hinz B, Brune K. Cyclooxygenase-2--10 years later. *J Pharmacol Exp Ther* 2002;300:367-75.
 18. Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: Transducing biochemical selectivity into clinical read-outs. *J Clin Invest* 2001;108:7-13.
 19. Celotti F, Laufer S. The role of cyclooxygenase isozymes in the inflammatory reaction. *Life Sci* 2001;68:341-50.
 20. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and-2 by nonsteroidal anti-inflammatory drugs. *J Pharmacol Exp Ther* 1994;271:927-34.
 21. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. *Annu Rev Pharmacol Toxicol* 1998;38:97-120.
 22. Available from: <https://cdn1.sinobiological.com/styles/default/images/protein-structure/PTGS2-pro>